ERBB2 and breast cancer: In this context, AXL deletion in a preclinical model of HER2+ breast cancer almost completely abrogated the metastatic dissemination by blocking intravasation, extravasation and growth at the metastatic site [3], supporting a role for AXL in TGF-β-induced cell invasion.